RAPT Therapeutics, Inc. (RAPT) Depreciation & Amortization (CF) (2020 - 2024)
RAPT Therapeutics (RAPT) has disclosed Depreciation & Amortization (CF) for 5 consecutive years, with $284000.0 as the latest value for Q4 2024.
- Quarterly Depreciation & Amortization (CF) fell 12.07% to $284000.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $1.2 million through Dec 2024, down 3.19% year-over-year, with the annual reading at $1.2 million for FY2024, 1.32% down from the prior year.
- Depreciation & Amortization (CF) hit $284000.0 in Q4 2024 for RAPT Therapeutics, down from $300000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $400000.0 in Q2 2020 to a low of $196000.0 in Q4 2021.
- Historically, Depreciation & Amortization (CF) has averaged $270650.0 across 5 years, with a median of $292000.0 in 2020.
- Biggest five-year swings in Depreciation & Amortization (CF): crashed 50.0% in 2021 and later soared 57.56% in 2023.
- Year by year, Depreciation & Amortization (CF) stood at $265000.0 in 2020, then dropped by 26.04% to $196000.0 in 2021, then rose by 4.59% to $205000.0 in 2022, then soared by 57.56% to $323000.0 in 2023, then decreased by 12.07% to $284000.0 in 2024.
- Business Quant data shows Depreciation & Amortization (CF) for RAPT at $284000.0 in Q4 2024, $300000.0 in Q3 2024, and $300000.0 in Q2 2024.